Julian Baker's Net Worth

$1.39 Billion

Who is Julian Baker?

Julian Baker has an estimated net worth of $1.39 Billion. This is based on reported shares across multiple companies, which include Seagen Inc., RHYTHM PHARMACEUTICALS, INC., BeiGene, Ltd., Invitae Corp, THERAVANCE INC, Prelude Therapeutics Inc, XOMA Corp, Kiniksa Pharmaceuticals, Ltd., Mirati Therapeutics, Inc., Zymeworks Inc., Intellia Therapeutics, Inc., Entrada Therapeutics, Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., AP PHARMA INC /DE/, ACADIA PHARMACEUTICALS INC, BIOCRYST PHARMACEUTICALS INC, INCYTE CORP, IDERA PHARMACEUTICALS, INC., DBV Technologies S.A., TScan Therapeutics, Inc., Neoleukin Therapeutics, Inc., Atreca, Inc., Aeglea BioTherapeutics, Inc., BELLICUM PHARMACEUTICALS, INC, HOOKIPA Pharma Inc., Talis Biomedical Corp, VIROPHARMA INC, Ardea Biosciences, Inc./DE, GENOMIC HEALTH INC, ALEXION PHARMACEUTICALS, INC., SYNAGEVA BIOPHARMA CORP, MADRIGAL PHARMACEUTICALS, INC., Principia Biopharma Inc., ADOLOR CORP, PHARMACYCLICS INC, AUXILIUM PHARMACEUTICALS INC, ALLOS THERAPEUTICS INC, Diadexus, Inc., TRANZYME INC, NEUROGEN CORP, Synvista Therapeutics, Inc., and TAPESTRY PHARMACEUTICALS, INC.

SEC CIK

Julian Baker's CIK is 0001087939

Past Insider Trading and Trends

2016 was Julian Baker's most active year for acquiring shares with 455 total transactions. Julian Baker's most active month to acquire stocks was the month of April. 2019 was Julian Baker's most active year for disposing of shares, totalling 379 transactions. Julian Baker's most active month to dispose stocks was the month of October. 2013 saw Julian Baker paying a total of $53,806,389,065.11 for 550,420,647 shares, this is the most they've acquired in one year. In 2013 Julian Baker cashed out on 117,349,500 shares for a total of $49,999,570,365.60, their largest year based on trade value.